Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
The Meals and Drug Administration (FDA) granted conventional approval to Imdelltra (tarlatamab-dlle) for grownup sufferers with extensive-stage small cell lung most cancers...
The U.S. Meals and Drug Administration has authorized Hyrnuo (sevabertinib) for the remedy of adults with regionally superior or metastatic non-squamous non–small...
